AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCL) is expected to announce its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $6.3120 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

AbCellera Biologics Stock Up 5.4%

ABCL stock opened at $3.10 on Tuesday. The stock’s 50 day moving average is $3.70 and its two-hundred day moving average is $4.28. AbCellera Biologics has a 52-week low of $1.89 and a 52-week high of $6.51. The company has a market capitalization of $927.92 million, a PE ratio of -5.44 and a beta of 0.80.

Institutional Investors Weigh In On AbCellera Biologics

Institutional investors have recently modified their holdings of the business. Lantern Wealth Advisors LLC bought a new position in AbCellera Biologics in the second quarter worth about $51,000. Invesco Ltd. raised its position in shares of AbCellera Biologics by 114.6% during the 1st quarter. Invesco Ltd. now owns 24,146 shares of the company’s stock worth $54,000 after purchasing an additional 12,893 shares during the period. Voleon Capital Management LP bought a new stake in shares of AbCellera Biologics in the 3rd quarter worth approximately $56,000. Cibc World Market Inc. boosted its position in AbCellera Biologics by 26.5% during the 4th quarter. Cibc World Market Inc. now owns 20,706 shares of the company’s stock valued at $71,000 after purchasing an additional 4,341 shares during the period. Finally, Sherbrooke Park Advisers LLC acquired a new position in AbCellera Biologics during the 3rd quarter valued at approximately $87,000. Institutional investors own 61.42% of the company’s stock.

Analyst Ratings Changes

ABCL has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of AbCellera Biologics from a “sell” rating to a “hold” rating in a research note on Saturday. Leerink Partners downgraded shares of AbCellera Biologics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.75.

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.